Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-151586 for Glabellar Lines in Toxin-Naïve Subjects
NCT05248880Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of trenibotulinumtoxinE in glabellar lines, sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale According to Both Investigator and Subject Assessments at Day 7, Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale According to Participant Assessment at Day 7 and 2 more. Started Mar 2022; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05248880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248880.